OHR Pharmaceutical Inc.

Ohr Pharmaceutical to Announce First Quarter 2017 Financial Results on February 14

Download PDF

NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for its first fiscal quarter ended December 31, 2016 before the market open on Tuesday, February 14, 2017.  The Company will also hold a live investor conference call and webcast at 7:45am Eastern Time.

Conference Call & Webcast
Tuesday, February 14 @ 7:45am Eastern Time
Domestic:   877-407-0789
International:   201-689-8562
Conference ID:   13655370
Webcast:   http://public.viavid.com/index.php?id=122974
     
Replays – Available through February 21, 2017
Domestic:   844-512-2921
International:   412-317-6671
Conference ID:   13655370
     

About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being evaluated in combination with anti-VEGF injections in a clinical program for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform.  Additional information about the company may be found at www.ohrpharmaceutical.com.

Contact:
Ohr Pharmaceutical Inc.
Investor Relations
888-388-2327
ir@ohrpharmaceutical.com

LifeSci Advisors, LLC
Michael Wood
646-597-6983
mwood@lifesciadvisors.com

Primary Logo

Source: Ohr Pharmaceutical, Inc.